行情

CBAY

CBAY

CymaBay
NASDAQ

实时行情|Nasdaq Last Sale

5.48
+0.02
+0.37%
已收盘, 16:00 11/19 EST
开盘
5.46
昨收
5.46
最高
5.72
最低
5.31
成交量
64.88万
成交额
--
52周最高
14.00
52周最低
4.230
市值
3.76亿
市盈率(TTM)
-3.8257
分时
5日
1月
3月
1年
5年

分析师评级

11位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

CBAY 新闻

  • 沪指低开低走 纽约联储主席称美经济面临下行风险
  • 新浪财经.1小时前
  • 击败亚马逊微软 谷歌赢得沃达丰数据服务大单
  • TechWeb.5小时前
  • 道明证券:"巨大风险事件"使风险对冲成2020年的佳选
  • 新浪财经综合.5小时前
  • 港交所:推出阿里巴巴集团控股有限公司股票期权
  • 新浪科技.6小时前

更多

所属板块

生物技术和医学研究
+2.16%
制药与医学研究
+0.78%

热门股票

名称
价格
涨跌幅

CBAY 简况

CymaBay Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies to treat metabolic diseases, including serious rare and orphan diseases. The Company's product candidates include Arhalofenate, MBX-8025 and MBX-2982. Arhalofenate is used to treat gout. MBX-8025 is a selective agonist for the peroxisome proliferator-activated receptor delta (PPARd). The Company has completed over five Phase I clinical studies and a Phase II clinical study for MBX-8025. MBX-2982 is an oral, G-protein coupled receptor agonist being evaluated as a therapeutic agent for patients with Type 2 diabetes (T2DM), with a dual mechanism, including direct effects and indirect effects mediated by gastrointestinal hormones known as incretins on glucose-dependent insulin secretion, as well as potentially beneficial effects on islet health. The Company has completed over four Phase I clinical studies and a Phase II clinical study for MBX-2982.
展开

Webull提供CymaBay Therapeutics Inc的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。